Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 4:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 252 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Phenylephrine Clear all
Completed Phase 1 Interventional

Phenylephrine Pediatric Pharmacokinetic Study

NCT00762567
View directory record Official record
Conditions
Rhinitis
Interventions
phenylephrine HCl
Drug
Lead sponsor
Johnson & Johnson Consumer and Personal Products Worldwide
Industry
Eligibility
2 Years to 17 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Oct 6, 2011 · Synced Oct 18, 2026, 4:57 AM EDT
Completed Not applicable Interventional Results available

Study for the Management of Pediatric Chronic Rhinosinusitis With or Without Balloon Sinuplasty

NCT01990820
View directory record Official record
Conditions
Rhinitis + Sinusitis, Pediatric Chronic Rhinosinusitis
Interventions
Acclarent Relieva Balloon Sinuplasty, Adenoidectomy + Maxillary Sinus Irrigation
Device · Procedure
Lead sponsor
Endeavor Health
Other
Eligibility
2 Years to 12 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 19, 2020 · Synced Oct 18, 2026, 4:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Clinical Study in Healthy Volunteers to Investigate the Neurocognitive Effects of a New Antiepileptic Drug: Brivaracetam

NCT00736931
View directory record Official record
Conditions
Epilepsy
Interventions
Brivaracetam, levetiracetam, lorazepam, placebo
Drug · Other
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 28, 2012 · Synced Oct 18, 2026, 4:57 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Vascular Function and Uterine Fibroids

NCT02123069
View directory record Official record
Conditions
Leiomyoma
Interventions
Brachial artery catheter, Acetylcholine, Nitroprusside, Norepinephrine, Nitroprusside and phenylephrine
Device · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
25 Years to 50 Years · Female only
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 2, 2018 · Synced Oct 18, 2026, 4:57 AM EDT
Completed Phase 3 Interventional Results available

Comparison of Intranasal Kovacaine Mist, and Placebo for Anesthetizing Maxillary Teeth in Adults

NCT01745380
View directory record Official record
Conditions
Anesthesia
Interventions
Tetracaine HCl 3% and Oxymetazoline HCl 0.05%, Placebo
Drug
Lead sponsor
St. Renatus, LLC
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
3
States / cities
Loma Linda, California • Baltimore, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 31, 2017 · Synced Oct 18, 2026, 4:57 AM EDT
Enrolling by invitation Phase 4 Interventional

The GUARDIAN Trial - Vasopressor Sub-Study

NCT04934748
View directory record Official record
Conditions
Blood Pressure
Interventions
Routine Blood Pressure Management, Tight Blood Pressure Management, Phenylephrine, Norepinephrine
Procedure · Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
45 Years and older
Enrollment
6,254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
4
States / cities
Omaha, Nebraska • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 29, 2025 · Synced Oct 18, 2026, 4:57 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of OMS302 in Subjects Undergoing Intraocular Lens Replacement With Phacoemulsification

NCT01454063
View directory record Official record
Conditions
Intraocular Lens Replacement
Interventions
OMS302, Placebo
Drug
Lead sponsor
Omeros Corporation
Industry
Eligibility
18 Years and older
Enrollment
405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
16
States / cities
Chandler, Arizona • Glendale, Arizona • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2014 · Synced Oct 18, 2026, 4:57 AM EDT
Recruiting Not applicable Interventional

Longitudinal Autonomic Characterization as a Predictor for Secondary Medical Complications Post-SCI

NCT07210437
View directory record Official record
Conditions
Spinal Cord Injuries
Interventions
Tests of sympathetic inhibition, Tests of above level sympathetic activation, Testing of below level sympathetic activation
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 18, 2026, 4:57 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Intranasal Steroids and Oxymetazoline in Allergic Rhinitis

NCT00584987
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
Fluticasone furoate, Placebo Fluticasone furoate, Oxymetazoline, Placebo Oxymetazoline
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 55 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 17, 2013 · Synced Oct 18, 2026, 4:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioavailability Study Comparing Modified Release To Immediate Release Apixaban Tablets In Healthy Volunteers

NCT00914641
View directory record Official record
Conditions
Thrombosis
Interventions
Apixaban IR, Apixaban MR1, Apixaban MR2, Apixaban MR3
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 45 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 25, 2009 · Synced Oct 18, 2026, 4:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of M207 With Intranasal Zolmitriptan in Healthy Volunteers

NCT03708744
View directory record Official record
Conditions
Migraine
Interventions
A: M207 3.8mg, 30 min, upper arm, B: M207 3.8 mg, 30 min, thigh, C: M207 3.8 mg, 1 hr, upper arm, D:zolmitriptan nasal spray
Drug
Lead sponsor
Zosano Pharma Corporation
Industry
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Neptune City, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 18, 2026, 4:57 AM EDT
Recruiting Phase 4 Interventional

The Choice of Vasopressor to Prevent Postoperative Acute Kidney Injury After Major Non-Cardiac Surgery

NCT06802224
View directory record Official record
Conditions
Anesthesia, Surgery With General Anesthesia, Noncardiac Surgery, Hypotension During Surgery, Acute Kidney Injury (AKI), Myocardial Injury After Noncardiac Surgery (MINS), Vasopressor
Interventions
Norepinephrine, Phenylephrine
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
18,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
9
States / cities
San Francisco, California • College Park, Maryland • Ann Arbor, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 18, 2026, 4:57 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Effectiveness of Kovacaine Nasal Spray for Dental Anesthesia

NCT01302483
View directory record Official record
Conditions
Dental Anesthesia Efficacy
Interventions
3% tetracaine HCL with 0.05% oxymetazoline HCL, Lidocaine Injection
Drug
Lead sponsor
St. Renatus, LLC
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jun 17, 2015 · Synced Oct 18, 2026, 4:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of Brimonidine on Intraocular Pressure When Dilating Routine Patients

NCT03139708
View directory record Official record
Conditions
Intraocular Pressure
Interventions
Alphagan, Phenylephrine, Tropicamide
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 50 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 9, 2018 · Synced Oct 18, 2026, 4:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study Designed to Study the Effects of Two Different Doses of CXA-101/Tazobactam, a Low Dose and a High Dose, on the QT/QTc Intervals in Healthy Subjects

NCT02508753
View directory record Official record
Conditions
Healthy
Interventions
CXA-101/tazobactam, Moxifloxacin, placebo
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 45 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Jan 26, 2017 · Synced Oct 18, 2026, 4:57 AM EDT
Recruiting Phase 1Phase 2 Interventional

Use of Phenylephrine for Assessment of Mitral Regurgitation Severity

NCT04500899
View directory record Official record
Conditions
Mitral Regurgitation
Interventions
Mydfrin
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 20, 2025 · Synced Oct 18, 2026, 4:57 AM EDT
Completed Phase 3 Interventional Results available

A Randomized, Double-Blind, 4-way Crossover Study to Evaluate the Efficacy of of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease

NCT01040728
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Olodaterol (BI1744) Low, Olodaterol (BI1744) High, Tiotropium 18 mcg, Placebo (for Olodaterol (BI1744)l), Placebo (for Tiotropium)
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
3
States / cities
Jasper, Alabama • Clearwater, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 30, 2014 · Synced Oct 18, 2026, 4:57 AM EDT
Completed Not applicable Interventional Results available

Ninvasive Cardiac Output Measurements During Cesarean Delivery Under Spinal Anesthesia.

NCT01928797
View directory record Official record
Conditions
Hypotension During Cesarean Delivery, Spinal Anesthesia
Interventions
Cardiac output monitor data
Device
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 14, 2017 · Synced Oct 18, 2026, 4:57 AM EDT
Completed Not applicable Interventional Results available

Goal-Directed Intraoperative Fluid Management Using FloTrac© Monitoring in High-Risk Neurosurgical Patients

NCT02701582
View directory record Official record
Conditions
Intracranial Aneurysm, Brain Edema, Scoliosis, Surgery
Interventions
Phenylephrine, Epinephrine, Albumin, Voluven, Normal Saline, Packed Red Blood Cells, FloTrac Monitor
Drug · Other · Device
Lead sponsor
NYU Langone Health
Other
Eligibility
15 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 18, 2026, 4:57 AM EDT
Completed Not applicable Interventional Results available

Four Way Crossover Closed Loop With Exercise Detection

NCT02862730
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Artificial Pancreas Controller in Dual Hormone Mode, Subject's insulin pump, Artificial Pancreas Controller in Single Hormone Mode, Artificial Pancreas Controller in Predictive Low Glucose Suspend Mode
Device
Lead sponsor
Oregon Health and Science University
Other
Eligibility
21 Years to 45 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 14, 2018 · Synced Oct 18, 2026, 4:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Effect of Antacid on Bioavailability of Febuxostat After Administration of a Febuxostat 80 mg Extended-Release Capsule

NCT02382640
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Febuxostat XR, Maalox Advance Regular Strength liquid
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 29, 2016 · Synced Oct 18, 2026, 4:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Effect of Timing of Food Intake on the Pharmacokinetics of Abiraterone Following Single-Dose Administration of Abiraterone Acetate Tablets in Healthy Caucasian and Japanese Men

NCT01575587
View directory record Official record
Conditions
Pharmacology
Interventions
Abiraterone: Treatment A, Abiraterone: Treatment B, Abiraterone: Treatment C, Abiraterone: Treatment D
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
25 Years to 35 Years · Male only
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Jan 10, 2014 · Synced Oct 18, 2026, 4:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Effects of Epetraborole on the QT Interval in Healthy Adult Subjects

NCT05995444
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Epetraborole and matching placebo, Epetraborole, Placebo, Moxifloxacin
Drug
Lead sponsor
AN2 Therapeutics, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 21, 2023 · Synced Oct 18, 2026, 4:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Study Comparing Aspirin and Effervescent Aspirin

NCT01081353
View directory record Official record
Conditions
Pharmacokinetics
Interventions
Acetylsalicylic Acid (Aspirin BAY1019036), Alka Seltzer Extra Strength, Aspirin Migraine, Aspirin Aspro
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 55 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 26, 2014 · Synced Oct 18, 2026, 4:57 AM EDT